Research Articles

Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys

Saimiri boliviensis monkeys were immunized with the yeast-expressed recombinant protein yP2P30Pv200(19). The antigen consisted of the C-terminus (amino acid Asn1622-Ser1729) of the merozoite surface protein 1 of the Plasmodium vivax Salvador I strain. Two universal T helper cell epitopes (P2 and P30) of tetanus toxin and six histidine residues for purification purposes were attached to the N- and C-termini, respectively. Four groups of five monkeys were given three immunizations at four-week intervals with either 250 microg of yP2P30Pv200(19) formulated with nonionic block copolymer P1005, 250 microg of antigen adsorbed to alum, 250 microg of antigen in phosphate-buffered saline (PBS), or PBS alone. Five weeks after the last immunization, each animal was inoculated with 100,000 parasitized erythrocytes of the Salvador I strain of P. vivax. Animals were splenectomized one week after challenge to increase parasite densities; after seven weeks of infection, animals were treated. Eighteen weeks later, the animals were rechallenged with the homologous parasite. Following the first challenge, three monkeys immunized with the antigen with P1005 were protected; no animals were protected from rechallenge. One monkey immunized with yP2P30Pv200(19) with alum was protected; no protection was seen after rechallenge. Two monkeys immunized with antigen alone were protected; none were protected from rechallenge. One control animal had a low parasite count following primary infection; none were protected against rechallenge. Adverse reactions were only observed with animals receiving P1005. It is proposed that splenectomy of the monkeys prevented adequate assessment of the efficacy of this antigen. Identification of a monkey host that supports high density parasitemia without splenectomy appears needed before further testing of blood-stage vaccines against P. vivax.

This article has been cited by other articles:

				W. E. Collins, J. S. Sullivan, E. Strobert, G. G. Galland, A. Williams, D. Nace, T. Williams, and J. W. Barnwell Studies on the Salvador I Strain of Plasmodium vivax in Non-human Primates and Anopheline Mosquitoes Am J Trop Med Hyg, February 1, 2009; 80(2): 228 - 235. [Abstract] [Full Text] [PDF]

				J. A. BONILLA, L. VALIDUM, R. CUMMINGS, and C. J. PALMER GENETIC DIVERSITY OF PLASMODIUM VIVAX PVCSP AND PVMSP1 IN GUYANA, SOUTH AMERICA Am J Trop Med Hyg, November 1, 2006; 75(5): 830 - 835. [Abstract] [Full Text] [PDF]

				A. VALDERRAMA-AGUIRRE, G. QUINTERO, A. GOMEZ, A. CASTELLANOS, Y. PEREZ, F. MENDEZ, M. AREVALO-HERRERA, and S. HERRERA ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT Am J Trop Med Hyg, November 1, 2005; 73(5_suppl): 16 - 24. [Abstract] [Full Text] [PDF]

				W. E. COLLINS, G. G. GALLAND, J. W. BARNWELL, V. UDHAYAKUMAR, J. S. SULLIVAN, D. NACE, J. E. TONGREN, T. WILLIAMS, J. ROBERTS, Y. P. SHI, et al. PRELIMINARY OBSERVATIONS ON THE EFFICACY OF A RECOMBINANT MULTISTAGE PLASMODIUM FALCIPARUM VACCINE IN AOTUS NANCYMAI MONKEYS Am J Trop Med Hyg, October 1, 2005; 73(4): 686 - 693. [Abstract] [Full Text] [PDF]

				S. Dutta, D. C. Kaushal, L. A. Ware, S. K. Puri, N. A. Kaushal, A. Narula, D. S. Upadhyaya, and D. E. Lanar Merozoite Surface Protein 1 of Plasmodium vivax Induces a Protective Response against Plasmodium cynomolgi Challenge in Rhesus Monkeys Infect. Immun., September 1, 2005; 73(9): 5936 - 5944. [Abstract] [Full Text] [PDF]

				W. E. COLLINS, J. S. SULLIVAN, G. G. GALLAND, A. WILLIAMS, D. NACE, T. WILLIAMS, and J. W. BARNWELL PLASMODIUM SIMIUM AND SAIMIRI BOLIVIENSIS AS A MODEL SYSTEM FOR TESTING CANDIDATE VACCINES AGAINST PLASMODIUM VIVAX Am J Trop Med Hyg, September 1, 2005; 73(3): 644 - 648. [Abstract] [Full Text] [PDF]

				C. Putaporntip, S. Jongwutiwes, N. Sakihama, M. U. Ferreira, W.-G. Kho, A. Kaneko, H. Kanbara, T. Hattori, and K. Tanabe Mosaic organization and heterogeneity in frequency of allelic recombination of the Plasmodium vivax merozoite surface protein-1 locus PNAS, December 10, 2002; 99(25): 16348 - 16353. [Abstract] [Full Text] [PDF]

				S. Dutta, L. A. Ware, A. Barbosa, C. F. Ockenhouse, and D. E. Lanar Purification, Characterization, and Immunogenicity of a Disulfide Cross-Linked Plasmodium vivax Vaccine Candidate Antigen, Merozoite Surface Protein 1, Expressed in Escherichia coli Infect. Immun., September 1, 2001; 69(9): 5464 - 5470. [Abstract] [Full Text] [PDF]